Exploring New Possibilities for Spinal Cord Recovery
Spinal cord injuries can have lasting effects on movement, sensation, and independence. Because the spinal cord has a limited ability to repair itself, researchers continue to explore regenerative approaches that may help support recovery.
One promising area of research involves exosomes derived from human umbilical cord mesenchymal stem cells (HUC-MSCs). Exosomes are tiny particles released by cells that carry important signals to other cells and may help influence inflammation, cell protection, and tissue repair. This 2024 Phase I clinical trial explored the use of these exosomes in people with complete subacute spinal cord injuries.
A First-in-Human Clinical Trial
The study included nine participants whose spinal cord injuries had occurred about three months earlier on average.
Researchers administered HUC-MSC-derived exosomes into the fluid surrounding the spinal cord and followed participants for 12 months. They looked at safety as well as changes in sensation, movement, independence, and bowel and bladder function.
Because this was a Phase I trial, the main goal was to determine whether this type of treatment could be given safely to patients.
Encouraging Results
The study reported a positive safety profile, with researchers finding that the treatment was well tolerated and that no adverse events were directly linked to the exosome therapy.
Several encouraging improvements were also observed during the follow-up period. Participants experienced significant improvements in light touch and pinprick sensation at both six and 12 months. Four participants also showed improvements in motor function.
Researchers also reported gains in overall independence, including areas related to self-care and bowel and bladder management. Bowel function improved significantly as well, which can be an important part of quality of life following spinal cord injury.
Together, these findings suggest that HUC-MSC-derived exosomes may have potential to support multiple areas of recovery.
How Could Exosomes Help?
Much of the regenerative interest surrounding MSCs may come from the signals they release rather than from the cells themselves.
Exosomes help carry these signals throughout the body. Researchers believe they may help regulate inflammation, protect nerve cells, and support communication between cells involved in healing.
This makes exosomes especially interesting as a cell-free regenerative approach. Instead of transplanting whole stem cells, researchers may be able to use the beneficial signals they naturally produce.
Why This Study Matters
One of the most exciting aspects of this research is that it represents the first human clinical trial using this type of umbilical cord MSC-derived exosome treatment for complete spinal cord injury.
The favorable safety findings and improvements in several sensory and functional measures provide an encouraging foundation for future clinical research.
As an early Phase I study, it was designed primarily to evaluate safety and included a small number of participants. Larger clinical trials will help researchers better understand how effective this approach may be and how it could potentially be used in regenerative medicine.
A Promising Direction in Regenerative Medicine
This study marks an important step forward for research involving MSC-derived exosomes.
In people with complete subacute spinal cord injuries, the treatment was well tolerated, while participants also showed encouraging improvements in sensation, independence, and bowel function during the 12-month follow-up period.
These early findings highlight the potential of umbilical cord MSC-derived exosomes as a cell-free regenerative therapy and support continued research into how they may one day contribute to recovery after neurological injury.
Source
Akhlaghpasand M, Tavanaei R, Hosseinpoor M, et al. Safety and potential effects of intrathecal injection of allogeneic human umbilical cord mesenchymal stem cell-derived exosomes in complete subacute spinal cord injury: a first-in-human, single-arm, open-label, phase I clinical trial. Stem Cell Research & Therapy. 2024 Aug 26;15(1):264. doi: 10.1186/s13287-024-03868-0. PMID: 39183334; PMCID: PMC11346059. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11346059/
Related Treatment Pages